Cardiol Therapeutics Inc. ( (CRDL) ) has released its Q4 earnings. Here is a breakdown of the information Cardiol Therapeutics Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™. In its latest earnings report, Cardiol Therapeutics Inc. reported a net loss of $36.7 million for 2024, an increase from the $28.1 million loss in 2023. The company’s cash and cash equivalents decreased to $30.6 million from $34.9 million in the previous year. Key financial highlights include a significant rise in general and administrative expenses to $26.3 million from $15.6 million, while research and development expenses remained stable at approximately $14 million. The company also raised $21.4 million through a public offering of common shares. Looking ahead, Cardiol Therapeutics remains committed to advancing its clinical programs and exploring strategic opportunities to enhance shareholder value.